Headquartered in Woburn, MA Fiscal year ends March NASDAQ: REPL replimune.com
Replimune Group, Inc. is a commercial-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment. The company's proprietary RPx platform is based on a potent herpes simplex virus type 1 (HSV-1) backbone designed to maximize immunogenic cell death and induce systemic anti-tumor immune responses. Replimune's lead product, TUDRIQEV (vusolimogene oderparepvec-wtpg), is a genetically modified HSV-1 oncolytic viral therapy approved under accelerated approval in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who have progressed on a PD-1-blocking antibody-based regimen. The company also has RP2 in its pipeline, an oncolytic immunotherapy that additionally expresses an anti-CTLA-4 antibody-like molecule, currently in a registration-directed Phase 2/3 trial for metastatic uveal melanoma. Replimune operates an in-house manufacturing facility and trades on the Nasdaq under the ticker REPL. Updated
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
Replimune Group, Inc. is a commercial-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment.
The Wall Street consensus 12-month price target for REPL is $23.33.
